Search Results for "Pharmac Cost Of Sativex In New Zealand"

21:37 EST 29th January 2015 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...


BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...


CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards (DHBs) over the next five years, says PHARMAC, New Zealand’s Pharmaceutical Management Agency...

PHARMAC Stressing Biosimilar Use For Savings

In its annual review, the New Zealand pharmaceutical management agency PHARMAC says it has made substantial savings from switching to generics and is also now emphasizing the use of biosimilars.

New Zealand proposal for sole supply of Remicade in DHB hospitals

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback.

Bayer’s Jadelle to be listed in New Zealand

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with Bayer New Zealand, the local subsidiary of German pharma major Bayer (BAYN: DE) for the listing...

PHARMAC’s Largest Single Deal Sees Nine Novartis Drugs Funded

PHARMAC, New Zealand’s pharmaceutical management agency, signed agreements with Novartis and Biogen Idec in mid-October that sees 10 new medicines funded at reduced prices, or wider access to eight ...

Savings from extended role exceed NZ$100 million, says NZ’s PHARMAC

District Health Boards are poised to save more than $100 million over five years as a result of New Zealand’s Pharmaceutical Management Agency PHARMAC’s expanded role, the agency reports in its An...

Major step forward for multiple sclerosis treatment in New Zealand

Funding for newer and more effective multiple sclerosis (MS) treatments has been approved by PHARMAC, New Zealand’s Pharmaceutical Management Agency.

New Zealand to fund Vidaza and Revlimid

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding two oncology products - azacitidine (Vidaza), lenalidomide (Revlimid) and thalidomide (Thalomid), ...

Matching PubMed Articles

Opioid substitution treatment in New Zealand: a 40 year perspective.

We provide an overview of the history and philosophy of the treatment for opioid dependence, which has been dominated by methadone substitution treatment for the past 40 years in New Zealand. Although...

Cost of traumatic brain injury in New Zealand: Evidence from a population-based study.

We aimed to estimate from a societal perspective the 1-year and lifetime direct and indirect costs of traumatic brain injury (TBI) for New Zealand (NZ) in 2010 projected to 2020.

Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand.

Researchers are commonly requested to describe potential benefits of their research for New Zealand in funding applications, but such benefits can be difficult to precisely determine. Recently, we rep...

Current trends and projections in the utilisation rates of hip and knee replacement in New Zealand from 2001 to 2026.

This study aimed to estimate the demand for total hip (THR) and knee replacements (TKR) by 2026 within New Zealand (NZ) and show how demographic factors are likely to influence this projection.

Community treatment orders in New Zealand: regional variability and international comparisons.

Community treatment orders (CTOs) have been used in New Zealand since 1992 and are now used in most Commonwealth countries. There is little research on the rate of use of CTOs in New Zealand. This stu...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement